Key result
A homozygous variant in the TMEM70 gene was identified in a 10-year-old male presenting with progressive hypertrophic cardiomyopathy, lactic acidosis, and hyperammonemia.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case highlights the clinical presentation of TMEM70 mutations, which include progressive hypertrophic cardiomyopathy and lactic acidosis, emphasizing the importance of genetic testing in pediatric patients with these features.
A 10-year-old male (III-4), born at term to consanguineous parents, was evaluated for a possible neurometabolic disorder (Fig. 1). He was initially referred to genetics clinic at 1 year with global developmental delay and cryptorchidism. He subsequently had multiple hospital admissions attributed to “metabolic crises,” at which he exhibited persistent hyperlactatemia and hyperammonemia. During one admission at 3 years, plasma lactate and pyruvate concentrations were increased at 9.5 mmol/L (reference interval: 0.5–2.0 mmol/L) and 175 μmol/L (reference interval: 30–90 μmol/L), respectively. Plasma amino acid and acylcarnitine analyses on a sample that was collected when the ammonia level was 39 μmol/L (reference interval: 0–55 μmol/L) were unremarkable. However, qualitative urine organic acid analysis demonstrated moderate 3-methylglutaconic aciduria (3-MGA). A lactic/pyruvic acidemia gene sequencing panel was also negative. Brain MRI showed mild periventricular leukomalacia. Echocardiogram performed at this time was unremarkable; however, repeated echocardiogram at 9 years showed left and right ventricular hypertrophy with normal ejection fraction. Further interrogation of the family history was remarkable for 2 miscarriages in the first trimester and an elder sibling (III-2) who died at 7 years due to lactic acidosis of unclear etiology. In addition, there was a younger male sibling (III-8) with a similar clinical presentation and unremarkable metabolic workup, with the exception of trace levels of 3-MGA in urine during an episode of hyperammonemia (95 μmol/L). The proband also had a maternal cousin who presented to another center with primary lactic acidosis, hyperammonemia, hearing impairment, mild aortic regurgitation, and left ventricular hypertrophy. His plasma amino acids and acylcarnitine profiles were unremarkable during an episode of mild hyperammonemia (plasma ammonia: 68 μmol/L; reference interval: 0–55 μmol/L). Whole-exome sequencing analysis in this individual revealed a homozygous variant in the TMEM70 gene (III-10). This prompted targeted testing of the proband and his younger sibling that confirmed the presence and segregation of the same homozygous variant (TMEM70: NM_017866.5: c.479A>C, p.His160Pro). According to American College of Medical Genetics guidelines, this variant was classified as likely pathogenic. Pedigree of family presented in this report. The pedigree shows the segregation of the homozygous variant in the affected siblings and their cousin, as indicated by the genotype. Dark-filled squares denote affected status, whereas dotted squares and cycles denote carrier status of the parents. M, months at last follow-up or death; Y, years. Pedigree of family presented in this report. The pedigree shows the segregation of the homozygous variant in the affected siblings and their cousin, as indicated by the genotype. Dark-filled squares denote affected status, whereas dotted squares and cycles denote carrier status of the parents. M, months at last follow-up or death; Y, years. Pathogenic variants in the nuclear TMEM70 gene cause autosomal recessive mitochondrial complex V (ATP synthase) deficiency (OMIM 612418) (1, 2). Patients with biallelic variants in TMEM70 often present with hypertrophic cardiomyopathy, which may evolve in utero (3, 4). Prematurity, intrauterine growth restriction, hypotonia, hypospadias, and cryptorchidism are additional notable findings (3). Recent studies have expanded the phenotype to include infantile-onset cataract, hypertonia, and limb contraction (3). Despite the wide range of clinical presentations, the most common findings include neurological impairment, congenital hypertrophic cardiomyopathy, lactic acidosis, hyperammonemia, and increased urine 3-MGA excretion (3, 4). Oxidative phosphorylation is the primary source of ATP. The oxidative phosphorylation apparatus is composed of 5 multisubunit complexes encoded by mitochondrial and nuclear genes (3). Complex V transfers protons to the inner mitochondrial membrane for conversion of ADP and inorganic phosphate to ATP. TMEM70 is a mitochondrial transmembrane protein involved in the assembly and stabilization of complex V (Fig. 2). Biochemical perturbations observed in complex V deficiency reflect generalized mitochondrial dysfunction—chronic lactic or pyruvic acidosis with 3-MGA excretion, as observed in the 2 affected siblings. Definitive diagnosis is established by molecular analysis of TMEM70 (3) or demonstration of reduced ATP synthase activity in cultured fibroblasts. Metabolic sequalae of defective TMEM70. Pyruvate produced from glycolysis enters the mitochondrial matrix and tricarboxylic acid (TCA) cycle at the level of acetyl-CoA. Reducing equivalents in the form of NADH and FADH2 are substrates for oxidative phosphorylation (OXPHOS). Defective TMEM70 impairs assembly of complex V, resulting in ATP deficits and lactic acid production. IM, inner mitochondrial membrane; OM, outer mitochondrial membrane. Metabolic sequalae of defective TMEM70. Pyruvate produced from glycolysis enters the mitochondrial matrix and tricarboxylic acid (TCA) cycle at the level of acetyl-CoA. Reducing equivalents in the form of NADH and FADH2 are substrates for oxidative phosphorylation (OXPHOS). Defective TMEM70 impairs assembly of complex V, resulting in ATP deficits and lactic acid production. IM, inner mitochondrial membrane; OM, outer mitochondrial membrane. Treatment of complex V deficiency currently involves a mitochondrial cocktail comprising multivitamins, levocarnitine, coenzyme Q-10, creatine, and sodium bicarbonate. Patients with cardiomyopathy are evaluated by echocardiogram and electrocardiography and managed based on the degree of cardiac decompensation. Seizures are treated with antiepileptics. The prognosis is variable; neonatal death is not uncommon, although some patients survive into early adulthood (1). Our patient was treated with levocarnitine, biotin, citrate, sodium bicarbonate, coenzyme Q-10, and carbamazepine. At 9 years, he underwent right scrotal orchiopexy to correct his cryptorchidism. Unfortunately, he died at 10 years of choking episodes that required cardiopulmonary resuscitation for several minutes followed by brain death. The family was referred for genetic counseling to consider future preventive measures. All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. N. Almontashiri, financial support. Upon manuscript submission, all authors completed the author disclosure form. Disclosures and/or potential conflicts of interest: R.W.A. Peake, Clinical Chemistry, AACC. None declared. None declared. None declared. The Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia through the project number 821. None declared. None declared. The authors extend their appreciation to the Deputyship for Research and Innovation, Ministry of Education in Saudi Arabia, for funding this research work through project number 821.
No takes yet. Share an insight, caveat, or question.
AlFaris et al. (2021) conducted a case report in Progressive Hypertrophic Cardiomyopathy and Lactic Acidosis (n=1). TMEM70 homozygous variant (c.479A>C, p.His160Pro) was evaluated. A homozygous variant in the TMEM70 gene was identified in a 10-year-old male presenting with progressive hypertrophic cardiomyopathy, lactic acidosis, and hyperammonemia.
Synapse has enriched 10 related papers. Consider them for comparative context: